Jump to content

Mirtazapine: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
← Older edit

MDElliottMD (talk | contribs)

3 user groups
5,189 edits
VisualWikitext
Comprehensive categorization: +Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs)
parser-claude: Mirtazapine MedTemplate refill, Top 300 stub upgrade
 
Line 1: Line 1:
{{MedTemplate
{{MedTemplate
| generic           = Mirtazapine
| generic           = Mirtazapine
| brand             = Remeron
| brand             = Remeron (US brand discontinued; generic widely available), Remeron SolTab (ODT)
| structure         =  
| structure         =
| classes           = NaSSA, Antidepressant, Sedative-Hypnotic
| classes           = [[:Category:Tetracyclic antidepressants|Tetracyclic antidepressant]], [[:Category:Antidepressants|Antidepressant]], [[:Category:Sleep aids|Sleep aid (off-label)]]
| mechanism          = Alpha-2 antagonist; H1/5-HT2/5-HT3 antagonist
| uses              = <vote slug="major-depressive-disorder-use">Major depressive disorder (FDA)</vote>, <vote slug="insomnia-mirtazapine-use">Insomnia adjunct (off-label; particularly with concurrent depression)</vote>, <vote slug="anxiety-adjunct-mirtazapine-use">Anxiety disorder adjunct (off-label)</vote>, <vote slug="chemotherapy-induced-nausea-use">Chemotherapy-induced nausea (off-label)</vote>, <vote slug="appetite-stimulation-cachexia-use">Appetite stimulation in cancer or HIV cachexia (off-label, leveraging weight-gain side effect)</vote>, <vote slug="ptsd-sleep-disturbance-use">PTSD-related sleep disturbance (off-label)</vote>
| uses              =  
| starting_dose    = 15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. '''Counterintuitive dose paradox''': lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose
| starting_dose     =  
| preparations     = Tablets 7.5, 15, 30, 45 mg; orally disintegrating tablets (SolTab) 15, 30, 45 mg
| preparations      =  
| fda_max          = 45 mg/day
| fda_max           =  
| pill_id           =
| routes             =  
| routes           = Oral
| onset             =  
| onset             = Sleep effect from first dose; antidepressant effect over 1-4 weeks
| duration           =  
| duration         = 24 hours (HS dosing)
| halflife           =
| halflife          = 20-40 hours<ref name="remeron-label">FDA Prescribing Information, Remeron (mirtazapine), Organon/Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020415s029,021208s019lbl.pdf</ref>
| bioavailability    =
| bioavailability   = ~50% (oral; substantial first-pass)<ref name="remeron-label" />
| pregnancy         =  
| pregnancy        = Limited human data; some observational signals reassuring relative to other antidepressants.{{citation needed}}
| legal              =  
| legal             = [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="remeron-label" />
| intro              =
| mechanism        = <vote slug="mirtazapine-mech-claim">Atypical antidepressant with a multi-receptor mechanism: central α2-adrenergic autoreceptor antagonism (disinhibiting noradrenergic and serotonergic neuron firing), 5-HT2A and 5-HT2C antagonism (the antidepressant rationale and the side-effect-favorable profile), 5-HT3 antagonism (antiemetic and pro-appetite), and strong H1 antihistamine activity (the sedation and weight-gain mediators). Net effect raises synaptic serotonin and norepinephrine indirectly without reuptake inhibition.</vote> Lacks the sexual dysfunction, discontinuation syndrome, and nausea associated with SSRIs and SNRIs, the principal selling points. Weight gain and sedation are the dose-limiting features. Rare but recognized '''agranulocytosis''' warrants monitoring for sore throat, fever, and infection during the first months of therapy<ref name="remeron-label" />.
| pharmacokinetics   =  
| pharmacodynamics  =  
| indications        =  
| dosing             =  
| effects            =  
| interactions      = <pharmaInteractions/>
| pregnancy_details  =
| monitoring         =
| counseling        =
| anecdotes          =
| seealso            =
| references        =  
}}
}}


== References ==
<references />
[[Category:Tetracyclic antidepressants]]
[[Category:Antidepressants]]
[[Category:Antidepressants]]
[[Category:Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs)]]
[[Category:Sleep aids]]

Latest revision as of 06:55, 23 May 2026

Tetracyclic antidepressant, Antidepressant, Sleep aid (off-label)
Mirtazapine
Remeron (US brand discontinued; generic widely available), Remeron SolTab (ODT)

Experience

👥 No personal reports yet
⚕ No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Tetracyclic antidepressant, Antidepressant, Sleep aid (off-label)
Common uses
Major depressive disorder (FDA)0, Insomnia adjunct (off-label; particularly with concurrent depression)0, Anxiety disorder adjunct (off-label)0, Chemotherapy-induced nausea (off-label)0, Appetite stimulation in cancer or HIV cachexia (off-label, leveraging weight-gain side effect)0, PTSD-related sleep disturbance (off-label)0
Pharmacy
Starting dose
15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. Counterintuitive dose paradox: lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose
Preparations
Tablets 7.5, 15, 30, 45 mg; orally disintegrating tablets (SolTab) 15, 30, 45 mg
US FDA Max
45 mg/day
Pharmacology
Routes
Oral
Onset
Sleep effect from first dose; antidepressant effect over 1-4 weeks
Duration
24 hours (HS dosing)
Half-life
20-40 hours[1]
Bioavailability
~50% (oral; substantial first-pass)[1]
Pregnancy
Limited human data; some observational signals reassuring relative to other antidepressants.[citation needed]
Legal status
Rx-only in US. Carries the antidepressant Boxed Warning for suicidality in children, adolescents, and young adults[1]
Purported mechanism
Atypical antidepressant with a multi-receptor mechanism: central α2-adrenergic autoreceptor antagonism (disinhibiting noradrenergic and serotonergic neuron firing), 5-HT2A and 5-HT2C antagonism (the antidepressant rationale and the side-effect-favorable profile), 5-HT3 antagonism (antiemetic and pro-appetite), and strong H1 antihistamine activity (the sedation and weight-gain mediators). Net effect raises synaptic serotonin and norepinephrine indirectly without reuptake inhibition.0 Lacks the sexual dysfunction, discontinuation syndrome, and nausea associated with SSRIs and SNRIs, the principal selling points. Weight gain and sedation are the dose-limiting features. Rare but recognized agranulocytosis warrants monitoring for sore throat, fever, and infection during the first months of therapy[1].

References

  1. ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Remeron (mirtazapine), Organon/Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020415s029,021208s019lbl.pdf
Retrieved from "https://pharmacopedia.wiki/index.php?title=Mirtazapine&oldid=6668"